Navigation Links
NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
Date:3/28/2008

Data Analysis Shows Promise of Epiretinal Brachytherapy as NeoVista

Progresses with Phase III CABERNET Study

PALM BEACH, Fla., March 28 /PRNewswire/ -- NeoVista, Inc. released today to the eye community updated results from a one-year feasibility study of the company's novel epiretinal brachytherapy for the wet form of age-related macular degeneration (AMD) at the 31st Annual Macula Society Meeting in Palm Beach, Florida. The promising data from the study, which was initiated by NeoVista to test the efficacy and safety of their novel therapy when used in conjunction with Avastin(R) (bevacizumab), showed a marked improvement in mean visual acuity.

In the ongoing nonrandomized, multicenter feasibility study, 34 subjects with predominantly classic, minimally classic, or occult (with no classic) choroidal neovascularization (CNV) received a single 24 Gy treatment of NeoVista's epiretinal brachytherapy in combination with two injections of Avastin, one dose prior to or at the time of radiation delivery and another one month later, depending on which arm of the trial the patient was enrolled in.

After 12 months of follow-up on 33 of the trial participants, subjects had experienced a mean improvement in visual acuity of 10 letters using the Early Treatment Diabetic Retinopathy Study (ETDRS) test; 94 percent of patients lost fewer than 15 letters, 39 percent gained 15 or more letters, and 12 percent gained 30 or more letters. 76 percent of the patients in the study did not require additional injections of Avastin throughout the year.

Most adverse events were related to the vitrectomy procedure (retinal tear, retinal detachment, subretinal hemorrhage, and vitreous hemorrhage). No events related to radiation toxicity have been reported to date.

Jeffrey S. Heier, MD, a retinal specialist, partner at Ophthalmic Consultants of Boston and a consultant for NeoVista, presented the one-year data obtained from trial partic
'/>"/>

SOURCE NeoVista, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
9. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)... VYVANSE demonstrated significant improvement i...ewswire-FirstCall/ -- Shire plc (LSE: SHP,Nasdaq:...mpany, today,presented the results of a phase III ...icant improvements in Attention Deficit Hyperactiv... safety and efficacy,endpoints., "Adults with ADH...
(Date:5/8/2008)... NEW HAVEN, Conn., May 8 /PRNewswire-FirstCal...today announced the start of an investigator-spons...cer agent Cloretazine(R),(VNP40101M) in combinatio...sly untreated acute myelogenous leukemia (AML) and...ial is being conducted under the,direction of Elle...
(Date:5/8/2008)... Patch Formulation May Provide New Option for C...xposure When Using an Oral NSAID, TAMPA, Fla., Ma... ALO ),a leading global specialty pharmaceutical...resented this week at the American Pain Society an...y and positive pharmacokinetic,profile of Alpharma...
(Date:5/7/2008)... WASHINGTON, May 7 /- ...ecialty biopharmaceutical company, today,announced...ted to examine,treatment differences with DAYTRANA...boys and girls aged 6 to 12 years with Attention D... from the analysis reaffirmed,that DAYTRANA has an...
Breaking Medicine Technology:Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 2Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 3Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 4Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists 5Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7Optim To Assist Prairie Community Health Center with Construction Scope Development 928 1Optim To Assist Prairie Community Health Center with Construction Scope Development 928 2Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York 923 1Stevens Health Technology and Society roundtable 3A Sept 19 919 1Stevens Health Technology and Society roundtable 3A Sept 19 919 2Vitamin D Supplements May Lengthen Life 917 1Vitamin D Supplements May Lengthen Life 917 2
...ean-Francois Rossi Medical Hematology and Oncology...otein (CRP) is an acute-phase protein that has lon...tion. CRP measurement can complement a range of di...reatment. However, as economic rationalization be...r, it is apparent that such areas of frequent labo...
...auer Contributing Editor ,Since the first syst...volutionized clinical medicine and patient care. D...universally available, and blood gases were consid...cally ill patients," according to a www.bloodgas.o...he blood gas analysis system., ,Blood gas test...
Other Medicine Technology:Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 2Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 3Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 4Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 2Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 3Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 4
(Date:5/9/2008)... take up the habit , , FRIDAY, May 9 (He...spread anti-smoking messages in their everyday con...according to a U.K. study. , The study inclu...chools in western England and Wales. At 30 of the ... training about the risks of smoking, the economic...
(Date:5/9/2008)...all/ -- Alseres,Pharmaceuticals, Inc. (Nasdaq: AL...ence call on Thursday, May 15th, 2008 at 9:00am ED...8 and discuss other matters related to,the Company...070608/NEF043LOGO ), To access the conference ca...325-4817 international. The code for this conferen...
(Date:5/9/2008)...mark Opportunity Partners,LLC, the investment man...unity Fund, Ltd. and Xmark JV Investment Partners,...nitiatives outlined in the press release,issued by...08 with respect to,executive base compensation, ca...nd the streamlining of expenditures., "Management...
(Date:5/9/2008)... and sensor standardization, creates p...lif., May 9 /PRNewswire-FirstCall/ -- Saint Barnab...e CO-Oximetry and,Measure-Through-Motion-and-Low-P...tion of Saint Barnabas Medical Center,s hospital-w...he New Jersey-based hospital performed an,extensiv...
Breaking Medicine News(10 mins):Health News:Training Student Leaders Cuts Peers' Smoking Rates 2Health News:Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call 2Health News:Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call 3Health News:Saint Barnabas Medical Center Converts to Masimo SET Technology - Establishing a Foundation for the Future of Pulse Oximetry 2Health News:Saint Barnabas Medical Center Converts to Masimo SET Technology - Establishing a Foundation for the Future of Pulse Oximetry 3Health News:Saint Barnabas Medical Center Converts to Masimo SET Technology - Establishing a Foundation for the Future of Pulse Oximetry 4Health News:Saint Barnabas Medical Center Converts to Masimo SET Technology - Establishing a Foundation for the Future of Pulse Oximetry 5
...proposes to set up quality hospitals on the model ...w Delhi, in Patna//, Raipur, Bhopal, Bhubaneshwar,...astha Sureksha Yojna (PMSSY), Union Minister for H...adoss has said. In a written reply to questions r...
...rd of India (AWBI) has started a pilot project in ... a new anti-rabies// oral bait vaccine that will b... and community dogs are being sterilized in India,...ommunity dog population in the country is estimate...
More Evidence of Racial Discrimination in the NHS
...n known to give a boost to the body’s immunity esp...ood health//. Now, a Christchurch researcher has d...ing of Vitamin C, demonstrating that apart from ma...may also help fight cancer. Margaret Vissers from...
Other Medicine News:Health News:More Evidence of Racial Discrimination in the NHS 2
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F.
...f todays cardiac surgery patients require progress...d speedy return to everyday life. Since the intro...nicians have been able to provide nearly 400,000 C... Faster ambulation , Shorter hospital stays ,...
...DSi is an all-digital Fundus camera system that of... an efficient workflow. The Canon CF-60DSi come...es SLR digital camera features a "full frame CMOS ...ew ICG unit, which features a near-infrared digita...
...erts are an ophthalmologic medical device designed...1.00 to -3.00 diopters.* When placed in the cornea... zone, the product reshapes the anterior surface o...escription inserts, each having an arc length of 1...
Medicine Products: